| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/03/2009 | WO2009108932A2 Selectin ligands useful in the diagnosis and treatment of cancer |
| 09/03/2009 | WO2009108868A2 Radiolabeled hedgehog derivatives for imaging and therapy |
| 09/03/2009 | WO2009108838A1 Bridged, bicyclic heterocyclic or spiro bicyclic heterocyclic derivatives of pyrazolo[1,5-a]pyrimidines, methods for preparation and uses thereof |
| 09/03/2009 | WO2009108827A1 Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof |
| 09/03/2009 | WO2009108807A1 Glycopeptides and methods of making and using them |
| 09/03/2009 | WO2009108762A2 Methods and compositions for treatment of retinoid-responsive conditions |
| 09/03/2009 | WO2009108706A2 Methods for inhibiting six 1 and eya proteins |
| 09/03/2009 | WO2009108656A1 Metastasis inhibition preparations and methods |
| 09/03/2009 | WO2009108633A2 Sphingosine 1-phosphate antagonism |
| 09/03/2009 | WO2009108388A2 Enzymatic production or chemical synthesis and uses for 5,7-dienes and uvb conversion products thereof |
| 09/03/2009 | WO2009108384A2 Compounds and compositions that cause non-apoptotic cell death and uses thereof |
| 09/03/2009 | WO2009108360A2 Inhibition of post-radiation tumor growth |
| 09/03/2009 | WO2009107850A2 Fused heterocyclic derivative and use thereof |
| 09/03/2009 | WO2009107322A1 Pharmaceutical composition for treatment of cancer |
| 09/03/2009 | WO2009107262A1 Anticancer composition containing 3”-methylated epigallocatechin gallate |
| 09/03/2009 | WO2009107223A1 Method of producing ceramide |
| 09/03/2009 | WO2009107139A1 Rgd-(bacterio)chlorophyll conjugates for photodynamic therapy and imaging of necrotic tumors |
| 09/03/2009 | WO2009106817A2 Compound |
| 09/03/2009 | WO2009106773A2 Transgenic non-human mammal for the constant region of the g-class human immunoglobulin heavy chain and applications thereof |
| 09/03/2009 | WO2009106752A2 Derivatives of 2-heteroaroyl-imidazol[1,2-a]pyridine, preparation thereof and therapeutic application thereof |
| 09/03/2009 | WO2009106751A2 Derivatives of n-heterocyclic-6-heterocyclic-imidazo[l,2- a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof |
| 09/03/2009 | WO2009106750A2 Derivatives of 6-heterocyclic-imidazo[l,2-a]pyrroine-2-carboxamides, preparation thereof and therapeutic application thereof |
| 09/03/2009 | WO2009106749A2 Derivatives of n-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof |
| 09/03/2009 | WO2009106748A2 Derivatives of n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof |
| 09/03/2009 | WO2009106708A2 Azetidine derivatives, their preparation and their application in therapy |
| 09/03/2009 | WO2009106624A1 Anticancer agent |
| 09/03/2009 | WO2009106586A1 Quinolines as inhibitors of farnesyl pyrophosphate synthase |
| 09/03/2009 | WO2009106579A1 Methods for prognosing the status of tumor patients |
| 09/03/2009 | WO2009106577A1 Imidazo [1,2-b] pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease |
| 09/03/2009 | WO2009106566A2 Therapy selection method |
| 09/03/2009 | WO2009106362A1 Dna vaccine for the therapy and prophylaxis of cervical cancer and the premalignant precursors thereof |
| 09/03/2009 | WO2009105969A1 Epothilone analogues, their pharmaceutical compositions, their use and their preparations |
| 09/03/2009 | WO2009105937A1 A vinorelbine soft capsule and its preparation method and application. |
| 09/03/2009 | WO2009105936A1 The use of phenolic glycosides derivatives in the manufacture of compositions for treating cell proliferation diseases |
| 09/03/2009 | WO2009105912A1 A fat emulsion containing ganoderma spore oil, its quality control methods and its use |
| 09/03/2009 | WO2009089383A3 Inhibitors of carbonic anhydrase ix |
| 09/03/2009 | WO2009076397A9 Antiviral activity of cyclopentene nitro-ester and derivatives |
| 09/03/2009 | WO2009076234A3 Synthesis methods of histone deacetylase inhibitors (hdacis) |
| 09/03/2009 | WO2009070045A3 Imidazole derivatives, process for their preparation, and thier pharmaceutical use |
| 09/03/2009 | WO2009067543A3 Treatment of histone deacetylase mediated disorders |
| 09/03/2009 | WO2009067520A3 Peptides specific for hepatocellular carcinoma cells and applications thereof |
| 09/03/2009 | WO2009065561A3 System for delivery into a xcr1 positive cell and uses thereof |
| 09/03/2009 | WO2009064590A3 Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer |
| 09/03/2009 | WO2009063492A9 Novel agents for treatment of ailments and dysfunctions |
| 09/03/2009 | WO2009061996A3 Antibodies that bind human dendritic and epithelial cell 205 (dec-205) |
| 09/03/2009 | WO2009049742A3 Use of melanotrophin-potentiating factor as a therapeutic agent |
| 09/03/2009 | WO2009046829A3 Casoxin d as a therapeutic agent |
| 09/03/2009 | WO2009043480A3 Use of leptin (22-56 ) as a therapeutic agent |
| 09/03/2009 | WO2009043469A3 Use of pneumadin as a therapeutic agent |
| 09/03/2009 | WO2009040018A3 Use of a peptide as a therapeutic agent |
| 09/03/2009 | WO2009040017A3 Use of a peptide as a therapeutic agent |
| 09/03/2009 | WO2009039993A3 Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 09/03/2009 | WO2009039992A3 Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 09/03/2009 | WO2009039988A3 Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection |
| 09/03/2009 | WO2009033805A3 Use of somatostatin-14 as a therapeutic agent |
| 09/03/2009 | WO2009033802A3 Antide as a therapeutic agent |
| 09/03/2009 | WO2009033801A3 Syndyphalin alone or in combination with antide as a therapeutic agent |
| 09/03/2009 | WO2009033755A3 Use of l-carnosine as a therapeutic agent |
| 09/03/2009 | WO2009033741A3 Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s) |
| 09/03/2009 | WO2009033737A3 Use of gluten exorphin c : as a therapeutic agent |
| 09/03/2009 | WO2009033731A3 Use of a laminin peptide as a therapeutic agent |
| 09/03/2009 | WO2009033723A3 Use of aip2 as a therapeutic agent |
| 09/03/2009 | WO2009033714A3 Use of a peptide as a therapeutic agent |
| 09/03/2009 | WO2009033692A3 Use of the peptides fibrinopeptide a and pyx-i as a therapeutic agents |
| 09/03/2009 | WO2009033665A3 Use of a rgd-peptide and/or parathyroid hormone (1-34 ) as anti-hiv agent |
| 09/03/2009 | WO2009033656A3 Use of follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumoniae infection |
| 09/03/2009 | WO2009021728A3 Targeted block copolymer micelles |
| 09/03/2009 | WO2009015981A3 Treatment of pediatric tumors |
| 09/03/2009 | WO2009004057A3 Mutated dimeric prolactin receptor ligands |
| 09/03/2009 | WO2009003428A3 Substituted 6-anilinopurine derivatives as inhibitors of cytokinin oxidase/dehydrogenase and preparations containing these derivatives |
| 09/03/2009 | WO2009001219A3 Immunocytokines for cancer treatment in combination with chemotherapeutic agents |
| 09/03/2009 | WO2008120202A9 Antibodies, methods and kits for diagnosing and treating melanoma |
| 09/03/2009 | WO2006113204A3 Thymidine derivatives for treatmemt of kaposi's sarcoma |
| 09/03/2009 | US20090222931 Novel identified oncogene with kinase-domain (nok) |
| 09/03/2009 | US20090221841 2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumour action |
| 09/03/2009 | US20090221718 Metadherin polypeptides, encoding nucleic acids and methods of use |
| 09/03/2009 | US20090221708 Medicinal preparation |
| 09/03/2009 | US20090221702 Compounds |
| 09/03/2009 | US20090221698 Mannose derivatives for killing tumor cells |
| 09/03/2009 | US20090221696 Flavonoid isolated from Pteridophyta, Thelypteris torresiana; anticancer |
| 09/03/2009 | US20090221695 Chroman Derivatives as Estrogenic Compounds |
| 09/03/2009 | US20090221688 Pharmaceutical compositions containing docetaxel and a degradation inhibitor and a process for obtaining the same |
| 09/03/2009 | US20090221685 Oligomeric compounds and compositions for the use in modulation of micrornas |
| 09/03/2009 | US20090221682 DNA Vaccine for Cancer Therapy |
| 09/03/2009 | US20090221681 Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer |
| 09/03/2009 | US20090221678 target heat shock protein (hsp) 27 in vivo; antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA; injectable dosage unit form |
| 09/03/2009 | US20090221669 Disubstituted Aniline Compounds |
| 09/03/2009 | US20090221666 Stilbene derivatives and methods of inhibiting cancer cell growth and microbial growth |
| 09/03/2009 | US20090221657 Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I |
| 09/03/2009 | US20090221638 Crystalline form of a biphenyl compound |
| 09/03/2009 | US20090221633 Inhibitors of akt (protein kinase b) |
| 09/03/2009 | US20090221632 Bicyclo-Pyrazoles and Pharmaceutical Compositions Comprising Them |
| 09/03/2009 | US20090221630 Iap inhibitors |
| 09/03/2009 | US20090221628 Compositions and methods for treatment of prostate and breast cancer |
| 09/03/2009 | US20090221616 Quinazoline derivatives as egf and/or erbb2 tyrosine kinase inhibitors |
| 09/03/2009 | US20090221615 Combination anti-cancer agents |
| 09/03/2009 | US20090221614 Selective serine/threonine kinase inhibitors |
| 09/03/2009 | US20090221612 Certain substituted amides, method of making, and method of use thereof |
| 09/03/2009 | US20090221608 3-({4-[1-(2,2-difluoroethyl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propanenitrile, used as serine/threonine protein kinase inhibitors, for the treatment of disease states associated with abnormal cell growth such as cancer |
| 09/03/2009 | US20090221604 Thiazole Compounds and Their Use as PGD2 Antagonists |